Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy (GRECCAR14)

Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity. Surgery alone can cure only one out of two patients, radiochemotherapy improves the local control but the metastatic risk remains about 30% with enhanced postoperative morbidity and poor functional results. The …

proctectomy
total mesorectal excision
irinotecan
capecitabine
carcinoma
  • 0 views
  • 23 Oct, 2022
  • 14 locations
Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer. (PROPER)

At least 40% of the patients with prostate cancer (PC) present with positive lymph nodes (N1). The optimal treatment strategy for these patients remains controversial. Although androgen deprivation therapy (ADT) is still often initiated as only treatment, the results are disappointing. Recent studies support the use of more aggressive therapies …

androgens
external beam radiotherapy
prostatectomy
prostate carcinoma
antiandrogen therapy
  • 4 views
  • 23 Feb, 2022
  • 1 location
A Phase II Clinical Study of Stereotactic Radiation Therapy in Patients With High-risk Prostate Cancer

effectiveness and safety of SBRT with pelvic radiation and gross target volume(GTV) boost for high-risk prostate cancer patients yet. The investigators designed a phase II clinical study of SBRT with pelvic

  • 0 views
  • 14 Jul, 2022
  • 1 location
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II

Adjuvant radiotherapy (RT) plays an important role in reducing the risks of local recurrence after surgery in uterine cancers. Standard adjuvant pelvic radiation treatment targets the pelvic

adenocarcinoma
brachytherapy
cancer
endometrial adenocarcinoma
carcinoma
  • 0 views
  • 31 Oct, 2021
  • 5 locations
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer (DeCRESCEndo)

with uterine serous or carcinosarcoma histology. The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate < 10%, and patients will benefit

neutrophil count
cancer
carcinosarcoma
adenocarcinoma
hysterectomy
  • 0 views
  • 04 Oct, 2022
  • 1 location
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also

  • 2 views
  • 01 Feb, 2021
  • 1 location
Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy (PERN)

factor of anastomotic leakage and stenosis after rectal cancer surgery. Unhealthy anastomosis, with both ends of injured bowel segments after pelvic radiation, is a major concern. When

general anesthesia
fluorouracil
chemoradiotherapy
metastasis
cancer surgery
  • 0 views
  • 23 Feb, 2022
  • 1 location
Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

Pelvic radiation therapy (IMRT) if deemed necessary. Additionally, from Week 24-26, High Dose Radiation or IMRT will be used where appropriate. Patients will be monitored for toxicity and

metastasis
carcinoma
ovarian cancer
carboplatin
hysterectomy
  • 0 views
  • 25 Nov, 2021
  • 1 location
Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

telephone call. Then they will be contacted every 3 months for 1 year, and then every 6 months after that, for the rest of their life. Patients with cervical cancer with prior pelvic radiation and

measurable disease
pds0101
brachytherapy
liver metastases
metastasis
  • 15 views
  • 22 Oct, 2022
  • 1 location
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures.

monoclonal antibodies
  • 0 views
  • 04 Oct, 2022
  • 1 location